HER-2 阴性乳腺癌市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

HER-2阴性乳腺癌市场按治疗类型(化学疗法、放射疗法、激素疗法等)和地理位置进行细分。

HER-2 阴性乳腺癌市场快照

HER-2 Negative Breast Cancer Market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >8.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

人表皮生长因子受体 2 (HER-2) 阴性乳腺癌是指乳房中不含有高水平蛋白质 HER-2 的癌细胞。近十年的主要要求是在最大限度地控制症状和延长生存期的基础上进行改进。在所有类型的乳腺癌中,主要缺点之一是尽管早期乳腺癌的治疗有所进步,但患者中疾病的复发相当普遍。虽然 HER-2 阳性在所有地区都非常普遍,但 HER-2 阴性的存在也​​在稳步增长,预计该方向的临床进展和研究开发活动在预测期内将增长得更好。

报告范围

HER-2阴性乳腺癌在女性中发生率较低,约占所有类型乳腺癌的15%。所研究的市场按治疗类型和地理位置进行细分。

By Type of Treatment
Chemotherapy
Radiation
Hormonal Therapy
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

通过激素疗法治疗有望成为市场的主要贡献者

  • 市场上批准的几种药物可以阻断激素或降低体内激素水平,有助于治疗 HER-2 阴性乳腺癌。一些成熟的药物包括他莫昔芬、氟维司群、戈舍瑞林、奥拉帕尼等。
  • 一些在该细分市场推进药物开发和研发活动的公司包括阿斯利康、Biomarin、艾伯维、默克公司和 Tesaro,其产品处于临床开发后期。
  • 制造商面临的挑战之一是耐药性的发生是激素治疗中的常见问题。因此,预防或克服激素抵抗的激素疗法与激素疗法的联合疗法被高度考虑并正在开发中。
HER-2 Negative Breast Cancer Market

预计北美将在预测期内以类似趋势在市场中占有重要份额

由于更好的医疗保健基础设施以及越来越多的基金会和独立风险投资集团支持生物制药制造商,北美预计将在全球 HER-2 阴性乳腺癌市场占据主要市场份额。不同州的主要制造商的存在,从不同的风险合作伙伴那里获得资金,推动了与 HER-2 阴性乳腺癌相关的市场。根据美国癌症协会,2017-2018 年,美国黑人女性中 HER-2 阴性癌症的发生率是白人女性的两倍,在绝经前女性和 BRCA1 患者中也更常见基因突变。与此类人群相关的挑战是对已确定的 HER-2 阴性乳腺癌患者群体进行早期诊断和正确的治疗程序。

HER-2 Negative Breast Cancer Market

竞争格局

公司的主要重点是开发联合疗法,以克服市场上现有药物疗法的耐药性,从而促进靶向疾病治疗。这是通过市场参与者之间的协作和伙伴关系来完成的。该领域的一些主要公司包括阿斯利康、礼来公司、诺华公司、辉瑞、葛兰素史克等。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Breast Cancers

      2. 4.2.2 Medical Advancements by Breast Cancers Treatment

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Treatment

      2. 4.3.2 Less Awareness Regarding HER-2 Negative Breast Cancer

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type of Treatment

      1. 5.1.1 Chemotherapy

      2. 5.1.2 Radiation

      3. 5.1.3 Hormonal Therapy

      4. 5.1.4 Others

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca PLC

      2. 6.1.2 Celgene Corporation (Bristol Myers Squibb Company)

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 GlasxoSmithKline

      5. 6.1.5 Merck & Co., Inc.

      6. 6.1.6 Novartis AG

      7. 6.1.7 Pfizer

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The HER-2 Negative Breast Cancer Market market is studied from 2018 - 2026.

The HER-2 Negative Breast Cancer Market is growing at a CAGR of >8.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Eli Lilly and Company , AstraZeneca, GSK, Novartis AG , Pfizer are the major companies operating in HER-2 Negative Breast Cancer Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!